+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biopharmaceuticals Market - Growth, Trends, and Forecast (2020 - 2025)

  • PDF Icon


  • 114 Pages
  • August 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 5175477
The global biopharmaceuticals market is found witnessing a CAGR of 7.32%. The market is largely driven by the growing geriatric population, increasing burden of chronic diseases, and rising inclination toward targeted therapy. Also, the huge demand of biopharmaceutical is facilitated by an accelerating focus in research and related investment.

The ability of biopharmaceutical products to address previously untreatable conditions has introduced innovative drugs in the market. About 70% of the potential medicines in development represent novel approaches to addressing diseases in areas, such as neurology, cancer, diabetes, and immunology. Biopharmaceuticals have thus seen to reduce the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.

In addition, the market demand for biopharmaceuticals is increasing with the rising desire to circumvent both the side-effects associated with some small-molecule therapeutics and invasive surgical treatments. However, high cost, along with the difficulty of the development of a biopharmaceutical drug, is one growth limiting factor.

Key Market Trends

Monoclonal Antibodies is Expected to Hold a High Market Share During the Forecasted Period

Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.

Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.

The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. This application has improved the market scope for this particular enzyme in the recent years.

North America Dominates the Market and Expected to do the Same in the Forecast Period

North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. The United States has shown an incredible growth over the past several years. The country has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.

The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.

Competitive Landscape

The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Acceptance for Biopharmaceuticals
4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
4.2.3 Huge Market Demand
4.3 Market Restraints
4.3.1 High-end Manufacturing Requirements
4.3.2 Complicated and Cumbersome Regulatory Requirements
5.1 By Product Type
5.1.1 Monoclonal Antibodies Anti Cancer Monoclonal Antibodies Anti-inflammatory Monoclonal Antibodies Other Monoclonal Antibodies
5.1.2 Recombinant Growth Factors Erythropoietin Granulocyte Colony Stimulating Factor
5.1.3 Purified Proteins Leukemia Inhibitory Factor (LIF) P53 Protein P38 Protein Other Purified Proteins
5.1.4 Recombinant Proteins Serum Albumin Amyloid Protein Defensin Transferrin
5.1.5 Recombinant Hormones Recombinant Human Growth Hormones Recombinant Insulin Other Recombinant Hormones
5.1.6 Vaccines Recombinant Vaccines Cancer Vaccines Malaria Vaccines Ebola Vaccine Hepatitis B Vaccine Tetanus Vaccine Diptheria Vaccine Cholera Vaccine Other Recombinant Vaccines Conventional Vaccines Polio Vaccine Pox Vaccine Other Conventional Vaccines
5.1.7 Recombinant Enzymes Enterokinase Cyclase Caspase Cathepsin
5.1.8 Cell and Gene Therapies Allogeneic Products Autologous Products Acellular Products
5.1.9 Synthetic Immunomodulators Cytokines, Interferones, Interleukins
5.1.10 Other Product Types Blood Factors Other Product Types
5.2 By Therapeutic Application
5.2.1 Oncology
5.2.2 Inflammatory and Infectious Diseases
5.2.3 Autoimmune Disorders
5.2.4 Metabolic Disorders
5.2.5 Hormonal Disorders
5.2.6 Cardiovascular Diseases
5.2.7 Neurological Diseases
5.2.8 Other Diseases
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe United Kingdom Germany France Italy Spain Rest of Europe
5.3.3 Asia-Pacific India China Japan Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East & Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lily & Co.
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Novo Nordisk Inc.
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline PLC
6.1.10 F. Hoffmann-La Roche AG

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbvie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily & Co.
  • Johnson & Johnson
  • Novartis AG
  • Novo Nordisk Inc.
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche AG